---
schema_version: "secwatch.filing_event.v1"
accession: "0001534969-22-000122"
form_type: "8-K"
ticker: "SERA"
cik: "0001534969"
company_name: "SERA PROGNOSTICS, INC."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:24:12.917412+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sera Prognostics Q2 net loss widens to $11.5M; cash runway extended to 2026

## Summary
- Revenue of $78K, up from $20K in Q2 2021, but operating expenses rose to $11.8M from $7.4M.
- Net loss of $11.5M ($0.29/share) vs $6.3M a year ago; cash & securities at $121M as of June 30.
- PreTRM test now collects blood at 18-20 weeks; sensitivity ~90%, NPV 99% for preterm risk.
- Company streamlined operations to fund operations into 2026 without additional financing.
- Contracted several new self-insured employer plans for PreTRM testing as an advanced pregnancy benefit.

## SEC filing metadata
- accession: 0001534969-22-000122
- form_type: 8-K
- ticker: SERA
- cik: 0001534969
- company_name: SERA PROGNOSTICS, INC.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000122/0001534969-22-000122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000122/sera-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534969-22-000122
- JSON: https://secwatch.observer/filing/0001534969-22-000122.json
- Plain text: https://secwatch.observer/filing/0001534969-22-000122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.